Skip to main content
Erschienen in:

16.02.2021 | Ovarialkarzinom | Leitthema

Toxizität und Effektivität lokoregionaler Chemotherapien

verfasst von: PD Dr. med. P. Jo, Univ.-Prof. Dr. med. Jens Jakob

Erschienen in: Die Onkologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund und Fragestellung

Lokoregionäre Chemotherapieverfahren sind für Therapiesituationen entwickelt worden, in denen traditionelle Therapieansätze sich als nicht möglich oder effektiv erwiesen haben. Beispielhaft werden hier die hypertherme isolierte Extremitätenperfusion („isolated limb perfusion“, ILP) und die hypertherme intraperitoneale Chemotherapie (HIPEC) diskutiert.

Material und Methodik

Für dieses Manuskript wurde eine gezielte Analyse der aktuellen Literatur zu Effektivität, Toxizität und Weiterentwicklung von ILP und HIPEC durchgeführt.

Ergebnisse und Schlussfolgerung

Sowohl bei der ILP als auch der HIPEC haben sich über die letzten Jahre Indikationsstellung mit Patientenselektion und die Parameter der Prozeduren (z. B. applizierte Substanzen oder erreichte Maximaltemperaturen) deutlich gewandelt. Hierdurch konnte die Toxizität der Verfahren deutlich reduziert werden. Indikationsstellung und Durchführung regionaler Therapien müssen angesichts der Einführung neuer systemischer Therapieansätze (wie z. B. Immuntherapie) kontinuierlich reevaluiert werden.
Literatur
1.
Zurück zum Zitat Creech O Jr. et al (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616–632CrossRef Creech O Jr. et al (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616–632CrossRef
2.
Zurück zum Zitat Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42CrossRef Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42CrossRef
3.
Zurück zum Zitat Eggermont AM et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224(6):756–764 (discussion 764–5)CrossRef Eggermont AM et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224(6):756–764 (discussion 764–5)CrossRef
4.
Zurück zum Zitat Jakob J, Hohenberger P (2016) Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. Cancer 122(17):2624–2632CrossRef Jakob J, Hohenberger P (2016) Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. Cancer 122(17):2624–2632CrossRef
5.
Zurück zum Zitat Ruegg C et al (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4(4):408–414CrossRef Ruegg C et al (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4(4):408–414CrossRef
6.
Zurück zum Zitat Tracey KJ et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234(4775):470–474CrossRef Tracey KJ et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234(4775):470–474CrossRef
7.
Zurück zum Zitat Bonvalot S et al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16(7):1061–1068CrossRef Bonvalot S et al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16(7):1061–1068CrossRef
8.
Zurück zum Zitat Wieberdink J et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905–910CrossRef Wieberdink J et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905–910CrossRef
9.
Zurück zum Zitat Trabulsi NH et al (2012) Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol 106(8):921–928CrossRef Trabulsi NH et al (2012) Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol 106(8):921–928CrossRef
10.
Zurück zum Zitat Deroose JP et al (2015) Treatment modifications in tumour necrosis factor-alpha (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. Eur J Cancer 51(3):367–373CrossRef Deroose JP et al (2015) Treatment modifications in tumour necrosis factor-alpha (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. Eur J Cancer 51(3):367–373CrossRef
11.
Zurück zum Zitat Seinen JM et al (2018) Fractures after multimodality treatment of soft tissue sarcomas with isolated limb perfusion and radiation; likely to occur and hard to heal. Eur J Surg Oncol 44(9):1398–1405CrossRef Seinen JM et al (2018) Fractures after multimodality treatment of soft tissue sarcomas with isolated limb perfusion and radiation; likely to occur and hard to heal. Eur J Surg Oncol 44(9):1398–1405CrossRef
12.
Zurück zum Zitat Lejeune FJ et al (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6PubMed Lejeune FJ et al (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6PubMed
13.
Zurück zum Zitat Jakob J et al (2018) Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. Clin Sarcoma Res 8:12CrossRef Jakob J et al (2018) Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. Clin Sarcoma Res 8:12CrossRef
14.
Zurück zum Zitat Pflugfelder A et al (2013) Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11(6):1–116–1–126 Pflugfelder A et al (2013) Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11(6):1–116–1–126
15.
Zurück zum Zitat Kroon HM et al (2014) Isolated limb infusion: technical aspects. J Surg Oncol 109(4):352–356CrossRef Kroon HM et al (2014) Isolated limb infusion: technical aspects. J Surg Oncol 109(4):352–356CrossRef
16.
Zurück zum Zitat Moreno-Ramirez D et al (2010) Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 15(4):416–427CrossRef Moreno-Ramirez D et al (2010) Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 15(4):416–427CrossRef
17.
Zurück zum Zitat Deroose JP et al (2011) Long-term outcome of isolated limb perfusion with tumour necrosis factor‑α for patients with melanoma in-transit metastases. Br J Surg 98(11):1573–1580CrossRef Deroose JP et al (2011) Long-term outcome of isolated limb perfusion with tumour necrosis factor‑α for patients with melanoma in-transit metastases. Br J Surg 98(11):1573–1580CrossRef
18.
Zurück zum Zitat Tawbi HA et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18(11):1493–1501CrossRef Tawbi HA et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18(11):1493–1501CrossRef
19.
Zurück zum Zitat Smith HG et al (2019) PD‑1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. Clin Cancer Res 25(11):3443–3454CrossRef Smith HG et al (2019) PD‑1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. Clin Cancer Res 25(11):3443–3454CrossRef
20.
Zurück zum Zitat Hodi FS et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‑year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492CrossRef Hodi FS et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‑year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492CrossRef
21.
Zurück zum Zitat Grabellus F et al (2013) Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. Eur J Surg Oncol 39(1):61–67CrossRef Grabellus F et al (2013) Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. Eur J Surg Oncol 39(1):61–67CrossRef
22.
Zurück zum Zitat Pasquali S et al (2018) High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. Eur J Cancer 93:28–36CrossRef Pasquali S et al (2018) High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. Eur J Cancer 93:28–36CrossRef
23.
Zurück zum Zitat Jakob J et al (2014) Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. J Surg Oncol 109(8):786–790CrossRef Jakob J et al (2014) Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. J Surg Oncol 109(8):786–790CrossRef
24.
Zurück zum Zitat Leebmann H, Piso P (2018) PIPAC and HIPEC-competing or supplementary therapeutic procedures for peritoneal metastases. Chirurg 89(9):693–698CrossRef Leebmann H, Piso P (2018) PIPAC and HIPEC-competing or supplementary therapeutic procedures for peritoneal metastases. Chirurg 89(9):693–698CrossRef
25.
Zurück zum Zitat Sugarbaker PH, Ryan DP (2012) Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 13(8):e362–9CrossRef Sugarbaker PH, Ryan DP (2012) Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 13(8):e362–9CrossRef
26.
Zurück zum Zitat Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249(6):900–907CrossRef Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249(6):900–907CrossRef
27.
Zurück zum Zitat Raspé C, Flöther L, Schneider R, Bucher M, Piso P (2017) Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol 43(6):1013–1027CrossRef Raspé C, Flöther L, Schneider R, Bucher M, Piso P (2017) Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol 43(6):1013–1027CrossRef
29.
Zurück zum Zitat Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743CrossRef Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743CrossRef
30.
Zurück zum Zitat Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, De Forges H, Stanbury T, Paineau J, Glehen O (2019) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503CrossRefPubMed Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, De Forges H, Stanbury T, Paineau J, Glehen O (2019) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. https://​doi.​org/​10.​1200/​JCO.​2018.​36.​18_​suppl.​LBA3503CrossRefPubMed
31.
Zurück zum Zitat AWMF online (2019) S3-Leitlinie Kolorektales Karzinom Langversion 2.1 (AWMF-Registernummer: 021/007OL) AWMF online (2019) S3-Leitlinie Kolorektales Karzinom Langversion 2.1 (AWMF-Registernummer: 021/007OL)
32.
Zurück zum Zitat Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581CrossRef Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581CrossRef
33.
Zurück zum Zitat Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O, BIG RENAPE Group (2016) Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol 23(6):1971–1979. https://doi.org/10.1245/s10434-015-5081-3CrossRefPubMed Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O, BIG RENAPE Group (2016) Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol 23(6):1971–1979. https://​doi.​org/​10.​1245/​s10434-015-5081-3CrossRefPubMed
34.
Zurück zum Zitat Rau B, Loeffler M, Rau H‑G, Sulkowski U, Kuhlmann J, Weimann A, Keck T, Angele M, Topp SA, Koenigsrainer A, Kuhnt E, Kretzschmar A, Knoefel WT, Thuss-Patience PC (2015) Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: a randomized phase III study (GASTRIPEC). J Clin Oncol. https://doi.org/10.1200/jco.2015.33.15_suppl.tps4132CrossRef Rau B, Loeffler M, Rau H‑G, Sulkowski U, Kuhlmann J, Weimann A, Keck T, Angele M, Topp SA, Koenigsrainer A, Kuhnt E, Kretzschmar A, Knoefel WT, Thuss-Patience PC (2015) Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: a randomized phase III study (GASTRIPEC). J Clin Oncol. https://​doi.​org/​10.​1200/​jco.​2015.​33.​15_​suppl.​tps4132CrossRef
35.
Zurück zum Zitat Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T (2020) Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer 127:76–95CrossRef Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T (2020) Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer 127:76–95CrossRef
36.
Zurück zum Zitat van Driel WJ et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240CrossRef van Driel WJ et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240CrossRef
38.
Zurück zum Zitat Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A (2014) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14(14):183CrossRef Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A (2014) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14(14):183CrossRef
39.
Zurück zum Zitat Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20(7):e368–e377CrossRef Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20(7):e368–e377CrossRef
40.
Zurück zum Zitat Neuwirth MG et al (2017) Isolated limb perfusion and infusion for extremity soft tissue sarcoma: a contemporary systematic review and meta-analysis. Ann Surg Oncol 24(13):3803–3810CrossRef Neuwirth MG et al (2017) Isolated limb perfusion and infusion for extremity soft tissue sarcoma: a contemporary systematic review and meta-analysis. Ann Surg Oncol 24(13):3803–3810CrossRef
Metadaten
Titel
Toxizität und Effektivität lokoregionaler Chemotherapien
verfasst von
PD Dr. med. P. Jo
Univ.-Prof. Dr. med. Jens Jakob
Publikationsdatum
16.02.2021
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 4/2021
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-021-00903-0

Weitere Artikel der Ausgabe 4/2021

Die Onkologie 4/2021 Zur Ausgabe

Passend zum Thema

ANZEIGE

Synergien nutzen gegen Tumore

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

ANZEIGE

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

ANZEIGE

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! PP-RB-DE-2009